מן הרשת 04.08.202411:00 Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy This study retrospectively evaluated whether enfortumab vedotin (EV) monotherapy is effective as a late-line treatment according to prior treatment type in patients with advanced urothelial carcinoma (UC) Uro Today
מן הרשת 04.08.202410:58 Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer An Exploratory Analysis of TITAN Trial Uro Today
מן הרשת 04.08.202410:57 Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer The ASCO Post
מן הרשת 04.08.202410:56 Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma? עבודה יפה מאוד עם קריאה להמשיך במעקב בלבד ללא ניתוח במטופלים עם מוטציות המתוארות The ASCO Post
מן הרשת 10.06.202412:34 Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Oncology
מן הרשת 10.06.202412:34 HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Uro Today
מן הרשת 10.06.202412:33 Long-Course vs Short-Course Androgen Deprivation Therapy Plus Postoperative Radiotherapy for Prostate Cancer Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain Oncology
מן הרשת 10.06.202412:32 Short-Course vs No Androgen Deprivation Therapy Added to Postoperative Radiotherapy for Prostate Cancer Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear Oncology
מן הרשת 14.04.202411:58 לראשונה בביה"ח השרון: טיפול בכאבי כתפיים באמצעות שלט רחוק לראשונה במרפאות הכאב בבית החולים השרון מקבוצת כללית החלו לטפל בכאב עצבי כרוני בכתפיים ע"י השתלת אלקטרודה פריפרית לשיכוך כאב פת עכשיו
מן הרשת 31.03.202412:51 Genitourinary toxicity in patients receiving TURP for clinically localized prostate cancer Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review Uro Today
מן הרשת 31.03.202412:49 Hormonal Therapy Plus SBRT for Advanced Prostate Cancer Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer The ASCO Post
מן הרשת 31.03.202412:45 Differential Effectiveness by Risk Group? Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations European Urology Oncology
מן הרשת 31.03.202412:44 Incidence of pulmonary toxicity in bleomycin-containing regimens for testicular cancer with and without the use of growth factor Uro Today
מן הרשת 31.03.202412:43 Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology Uro Today
מן הרשת 31.03.202412:42 The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection Uro Today
תגובות אחרונות